Cosmetics tallow derivative use sanctioned regardless of countries' BSE status by FDA cmte.

TALLOW DERIVATIVE USE REGARDLESS OF COUNTRY's BSE STATUS RECOMMENDED narrowly by FDA's Transmissible Spongiform Encephalopathies Advisory Committee. At a meeting in Bethesda, Md. April 15-16, the committee voted 6-5 to allow sourcing of tallow derivatives in cosmetics, food, nutritional supplements and drugs "from any country, irrespective of BSE status," according to Committee Chairman Paul Brown, MD, National Institute of Neurological Disorders & Stroke. The panel's recommendation would reverse current FDA guidelines, which have established that bovine source materials for the manufacturing of tallow derivatives should not come from countries where cattle have been infected with BSE. The committee's proposal will be taken under advisement by FDA.